Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390026 | 0.90 | ALDH1A1 (0.47) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL9082494 | 0.90 | ALDH1A1 (0.49) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL17664440 | 0.89 | ALDH1A1 (0.45) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL4598114 | 0.86 | KDM4E (0.57) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL8148281 | 0.86 | CA1 (0.52) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL393432 | 0.85 | GSK3B (0.47) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL7014391 | 0.84 | KDM4E (0.54) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL25256914 | 0.83 | CA12 (0.61) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL536163 | 0.83 | S1PR3 (0.51) | KDM4EALDH1A1MAPTHSD17B10HPGD | |
| SCHEMBL5846153 | 0.83 | GAA (0.51) | KDM4EALDH1A1MAPTHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100304381-A1 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | Life Technologies Corporation (US) | 2010-12-02 | — | — | US | disclosed |
| US-7687236-B2 | Fluorescent nucleobase conjugates having anionic linkers | APPLIED BIOSYSTEMS, LLC (US) | 2010-03-30 | — | — | US | disclosed |
| EP-1317464-B1 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | APPLERA CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-1317464-B1 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | APPLERA CORP (US) | 2009-05-13 | — | — | EP | disclosed |
| US-20090092986-A1 | Fluorescent Nucleobase Conjugates Having Anionic Linkers | APPLIED BIOSYSTEMS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | US | disclosed |
| US-7429651-B2 | Fluorescent nucleobase conjugates having anionic linkers | APPLERA CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429651-B2 | Fluorescent nucleobase conjugates having anionic linkers | APPLERA CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1831183-A1 | 1,6-SUBSTITUTED (3R,6R)-3-(2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067462-A1 | 1,6 - SUBSTITUTED (3R,6R) -3- (2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006067462-A1 | 1,6 - SUBSTITUTED (3R,6R) -3- (2,3-DIHYDRO-1H-INDEN-2-YL)-2,5-PIPERAZINEDIONE DERIVATIVES AS OXYTOCIN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PRE-TERM LABOUR, DYSMENORRHEA AND ENDOMETRIOSIS | GLAXO GROUP LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| US-20050250119-A1 | Fluorescent nucleobase conjugates having anionic linkers | APPLERA CORPORATION (US) | 2005-11-10 | — | — | US | disclosed |
| US-6811979-B2 | NUCLEOTIDE DERIVATIVE FOR USE IN SEQUENCE DETERMINATION OF NUCLEIC ACID MOLECULE | APPLERA CORPORATION | 2004-11-02 | — | — | US | disclosed |
| EP-1317464-A2 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | Applera Corporation (US) | 2003-06-11 | — | — | EP | disclosed |
| US-20020102590-A1 | Fluorescent nucleobase conjugates having anionic linkers | PE CORPORATION (NY) (US) | 2002-08-01 | — | — | US | disclosed |
| WO-2002030944-A2 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | APPLERA CORPORATION (US) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242666-A1 | 1-6-Substituted (3R,6R)-3-(2,3-Dihydro-1H-Inden-2-Yl)-2,5-Piperazinedione Derivatives as Oxytocin Receptor Antagonists For the Treatment of Preterm Labour, Dysmenorrhea and Endometriosis | OXTR, OPRL1, GPER1 | KDM4E 2691/4885ALDH1A1 642/4885MAPT 4205/4885 |
| US-20050250119-A1 | Fluorescent nucleobase conjugates having anionic linkers | DNTT, DUT, NT5C3B | KDM4E 1295/4885ALDH1A1 2642/4885MAPT 4071/4885 |
| US-20100304381-A1 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS | DNTT, DUT, NT5C3B | KDM4E 1295/4885ALDH1A1 2642/4885MAPT 4071/4885 |
| US-20020102590-A1 | Fluorescent nucleobase conjugates having anionic linkers | DNTT, DUT, NT5C3B | KDM4E 1295/4885ALDH1A1 2642/4885MAPT 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.